Alternative Cell Sources for Liver Parenchyma Repopulation: Where Do We Stand?
Acute and chronic liver failure is a highly prevalent medical condition with high morbidity and mortality. Currently, the therapy is orthotopic liver transplantation. However, in some instances, chiefly in the setting of metabolic diseases, transplantation of individual cells, specifically functiona...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/9/3/566 |
id |
doaj-3a9b611eb3ec4afb8d4d9beec9cf19f3 |
---|---|
record_format |
Article |
spelling |
doaj-3a9b611eb3ec4afb8d4d9beec9cf19f32020-11-25T01:19:53ZengMDPI AGCells2073-44092020-02-019356610.3390/cells9030566cells9030566Alternative Cell Sources for Liver Parenchyma Repopulation: Where Do We Stand?Tine Tricot0Jolan De Boeck1Catherine Verfaillie2Stem Cell Institute Leuven, KU Leuven, 3000 Leuven, BelgiumStem Cell Institute Leuven, KU Leuven, 3000 Leuven, BelgiumStem Cell Institute Leuven, KU Leuven, 3000 Leuven, BelgiumAcute and chronic liver failure is a highly prevalent medical condition with high morbidity and mortality. Currently, the therapy is orthotopic liver transplantation. However, in some instances, chiefly in the setting of metabolic diseases, transplantation of individual cells, specifically functional hepatocytes, can be an acceptable alternative. The gold standard for this therapy is the use of primary human hepatocytes, isolated from livers that are not suitable for whole organ transplantations. Unfortunately, primary human hepatocytes are scarcely available, which has led to the evaluation of alternative sources of functional hepatocytes. In this review, we will compare the ability of most of these candidate alternative cell sources to engraft and repopulate the liver of preclinical animal models with the repopulation ability found with primary human hepatocytes. We will discuss the current shortcomings of the different cell types, and some of the next steps that we believe need to be taken to create alternative hepatocyte progeny capable of regenerating the failing liver.https://www.mdpi.com/2073-4409/9/3/566hepatocyte transplantationpreclinical mouse models for liver damageprimary human hepatocyteshepatocyte expansionipscsmscs |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tine Tricot Jolan De Boeck Catherine Verfaillie |
spellingShingle |
Tine Tricot Jolan De Boeck Catherine Verfaillie Alternative Cell Sources for Liver Parenchyma Repopulation: Where Do We Stand? Cells hepatocyte transplantation preclinical mouse models for liver damage primary human hepatocytes hepatocyte expansion ipscs mscs |
author_facet |
Tine Tricot Jolan De Boeck Catherine Verfaillie |
author_sort |
Tine Tricot |
title |
Alternative Cell Sources for Liver Parenchyma Repopulation: Where Do We Stand? |
title_short |
Alternative Cell Sources for Liver Parenchyma Repopulation: Where Do We Stand? |
title_full |
Alternative Cell Sources for Liver Parenchyma Repopulation: Where Do We Stand? |
title_fullStr |
Alternative Cell Sources for Liver Parenchyma Repopulation: Where Do We Stand? |
title_full_unstemmed |
Alternative Cell Sources for Liver Parenchyma Repopulation: Where Do We Stand? |
title_sort |
alternative cell sources for liver parenchyma repopulation: where do we stand? |
publisher |
MDPI AG |
series |
Cells |
issn |
2073-4409 |
publishDate |
2020-02-01 |
description |
Acute and chronic liver failure is a highly prevalent medical condition with high morbidity and mortality. Currently, the therapy is orthotopic liver transplantation. However, in some instances, chiefly in the setting of metabolic diseases, transplantation of individual cells, specifically functional hepatocytes, can be an acceptable alternative. The gold standard for this therapy is the use of primary human hepatocytes, isolated from livers that are not suitable for whole organ transplantations. Unfortunately, primary human hepatocytes are scarcely available, which has led to the evaluation of alternative sources of functional hepatocytes. In this review, we will compare the ability of most of these candidate alternative cell sources to engraft and repopulate the liver of preclinical animal models with the repopulation ability found with primary human hepatocytes. We will discuss the current shortcomings of the different cell types, and some of the next steps that we believe need to be taken to create alternative hepatocyte progeny capable of regenerating the failing liver. |
topic |
hepatocyte transplantation preclinical mouse models for liver damage primary human hepatocytes hepatocyte expansion ipscs mscs |
url |
https://www.mdpi.com/2073-4409/9/3/566 |
work_keys_str_mv |
AT tinetricot alternativecellsourcesforliverparenchymarepopulationwheredowestand AT jolandeboeck alternativecellsourcesforliverparenchymarepopulationwheredowestand AT catherineverfaillie alternativecellsourcesforliverparenchymarepopulationwheredowestand |
_version_ |
1725136769320484864 |